These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 29548066)
1. Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 2: Existing Experience and Considerations for Future Trials. Zhang I; Formenti SC; Knisely JPS Oncology (Williston Park); 2018 Mar; 32(3):e33-e37. PubMed ID: 29548066 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy Plus Stereotactic Radiosurgery: Building on the Promise of Precision Medicine for CNS Malignancies-PART 1: Principles of Combined Treatment. Zhang I; Formenti SC; Knisely JPS Oncology (Williston Park); 2018 Feb; 32(2):e28-e32. PubMed ID: 29492951 [TBL] [Abstract][Full Text] [Related]
3. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Qian JM; Yu JB; Kluger HM; Chiang VL Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122 [TBL] [Abstract][Full Text] [Related]
4. Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. Shi DD; Arnaout O; Bi WL; Buchbinder EI; Cagney DN; Insco ML; Liu D; Schoenfeld JD; Aizer AA World Neurosurg; 2020 Jul; 139():226-231. PubMed ID: 32330622 [TBL] [Abstract][Full Text] [Related]
5. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma. Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560 [TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419 [TBL] [Abstract][Full Text] [Related]
7. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis. El Rassy E; Farhat F; Kattan J Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477 [No Abstract] [Full Text] [Related]
8. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768 [TBL] [Abstract][Full Text] [Related]
9. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Mathew M; Tam M; Ott PA; Pavlick AC; Rush SC; Donahue BR; Golfinos JG; Parker EC; Huang PP; Narayana A Melanoma Res; 2013 Jun; 23(3):191-5. PubMed ID: 23462208 [TBL] [Abstract][Full Text] [Related]
10. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Patel KR; Lawson DH; Kudchadkar RR; Carthon BC; Oliver DE; Okwan-Duodu D; Ahmed R; Khan MK Neuro Oncol; 2015 Oct; 17(10):1312-21. PubMed ID: 26014049 [TBL] [Abstract][Full Text] [Related]
12. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases? Franceschini D; Franzese C; Navarria P; Ascolese AM; De Rose F; Del Vecchio M; Santoro A; Scorsetti M Cancer Treat Rev; 2016 Nov; 50():1-8. PubMed ID: 27566962 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. Amaral T; Tampouri I; Eigentler T; Keim U; Klumpp B; Heinrich V; Zips D; Paulsen F; Gepfner-Tuma I; Skardelly M; Tatagiba M; Tabatabai G; Garbe C; Forschner A Immunotherapy; 2019 Mar; 11(4):297-309. PubMed ID: 30606066 [TBL] [Abstract][Full Text] [Related]
14. Treatment of Melanoma CNS Metastases. Jang S; Atkins MB Cancer Treat Res; 2016; 167():263-79. PubMed ID: 26601867 [TBL] [Abstract][Full Text] [Related]
15. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215 [TBL] [Abstract][Full Text] [Related]
16. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540 [TBL] [Abstract][Full Text] [Related]
17. Radiosurgery and Immunotherapy in the Treatment of Brain Metastases. Ramakrishna R; Formenti S World Neurosurg; 2019 Oct; 130():615-622. PubMed ID: 31581411 [TBL] [Abstract][Full Text] [Related]
18. Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases. Alomari AK; Cohen J; Vortmeyer AO; Chiang A; Gettinger S; Goldberg S; Kluger HM; Chiang VL Cancer Immunol Res; 2016 Jun; 4(6):481-7. PubMed ID: 26994250 [TBL] [Abstract][Full Text] [Related]
19. Optimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases. ElJalby M; Pannullo SC; Schwartz TH; Parashar B; Wernicke AG World Neurosurg; 2019 Jul; 127():397-404. PubMed ID: 31004856 [TBL] [Abstract][Full Text] [Related]